RNA-based tools for nuclear reprogramming and lineage-conversion: Towards clinical applications

Journal of Cardiovascular Translational Research

Volumn 6, Issue 6, 2013, Pages 956-968

  Bernal, Juan A ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Induced pluripotent stem cells (iPSCs); Lineage conversion; Modified mRNA (modRNA); Reprogramming; Sendai virus; Trans differentiation

Indexed keywords

ADENOVIRUS VECTOR; DNA; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MICRORNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CELL LINEAGE; DNA INTEGRATION; GENE; GENE CONVERSION; GENETIC TRANSDUCTION; HUMAN; KLF4 GENE; LENTIVIRINAE; NONHUMAN; NUCLEAR REPROGRAMMING; OCT4 GENE; PLASMID; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RETROVIRUS; RNA SYNTHESIS; SENDAI VIRUS; SOX2 GENE; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

SENDAI VIRUS;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICRORNAS; NUCLEAR REPROGRAMMING; RNA; RNA, MESSENGER; SENDAI VIRUS; TRANSCRIPTION FACTORS;

EID: 84890550726     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9494-8     Document Type: Article

References (122)

1. Gu, Q.; Hao, J.; Zhao, X. Y.; et al. (2012). Rapid conversion of human ESCs into mouse ESC-like pluripotent state by optimizing culture conditions. Protein & Cell, 3, 71.
2. Thomson, J. A.; Itskovitz-Eldor, J.; Shapiro, S. S.; et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145.
3. Saric, T.; Frenzel, L. P.; Hescheler, J. (2008). Immunological barriers to embryonic stem cell-derived therapies. Cells, Tissues, Organs, 188, 78.
4. Giacomini, M.; Baylis, F.; Robert, J. (2007). Banking on it: public policy and the ethics of stem cell research and development. Social Science & Medicine, 65, 1490.
5. Cho, L. T.; Wamaitha, S. E.; Tsai, I. J.; et al. (2012). Conversion from mouse embryonic to extra-embryonic endoderm stem cells reveals distinct differentiation capacities of pluripotent stem cell states. Development, 139, 2866.
6. Murry, C. E.; Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell, 132, 661.
7. Yu, J.; Thomson, J. A. (2008). Pluripotent stem cell lines. Genes & Development, 22, 1987.
8. Gurdon, J. B. (1968). Transplanted nuclei and cell differentiation. Scientific American, 219, 24.
9. Gurdon, J. B. (1968). Changes in somatic cell nuclei inserted into growing and maturing amphibian oocytes. Journal of Embryology and Experimental Morphology, 20, 401.
10. Gurdon, J. B.; Elsdale, T. R.; Fischberg, M. (1958). Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature, 182, 64.
11. Campbell, K. H.; McWhir, J.; Ritchie, W. A.; Wilmut, I. (1996). Sheep cloned by nuclear transfer from a cultured cell line. Nature, 380, 64.
12. Takahashi, K.; Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663.
13. Liao, J.; Cui, C.; Chen, S.; et al. (2009). Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell, 4, 11.
14. Liu, H.; Zhu, F.; Yong, J.; et al. (2008). Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell, 3, 587.
15. Ezashi, T.; Telugu, B. P.; Alexenko, A. P.; Sachdev, S.; Sinha, S.; Roberts, R. M. (2009). Derivation of induced pluripotent stem cells from pig somatic cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 10993.
16. Kuo, C. H.; Deng, J. H.; Deng, Q.; Ying, S. Y. (2012). A novel role of miR-302/367 in reprogramming. Biochemical and Biophysical Research Communications, 417, 11.
17. Anokye-Danso, F.; Trivedi, C. M.; Juhr, D.; et al. (2011). Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell, 8, 376.
18. Hussein, S. M.; Nagy, A. A. (2012). Progress made in the reprogramming field: new factors, new strategies and a new outlook. Current Opinion in Genetics & Development, 22, 435.
19. Vierbuchen, T.; Wernig, M. (2011). Direct lineage conversions: unnatural but useful? Nature Biotechnology, 29, 892.
20. Weintraub, H.; Davis, R.; Tapscott, S.; et al. (1991). The myoD gene family: nodal point during specification of the muscle cell lineage. Science, 251, 761.
21. Najm, F. J.; Lager, A. M.; Zaremba, A.; et al. (2013). Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nature Biotechnology, 31, 426.
22. Yang, N.; Zuchero, J. B.; Ahlenius, H.; et al. (2013). Generation of oligodendroglial cells by direct lineage conversion. Nature Biotechnology, 31, 434.
23. Vierbuchen, T.; Ostermeier, A.; Pang, Z. P.; Kokubu, Y.; Sudhof, T. C.; Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 463, 1035.
24. Szabo, E.; Rampalli, S.; Risueno, R. M.; et al. (2010). Direct conversion of human fibroblasts to multilineage blood progenitors. Nature, 468, 521.
25. Qian, L.; Huang, Y.; Spencer, C. I.; et al. (2012). In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature, 485, 593.
26. Song, K.; Nam, Y. J.; Luo, X.; et al. (2012). Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature, 485, 599.
27. Gonzalez, F.; Boue, S.; Izpisua Belmonte, J. C. (2011). Methods for making induced pluripotent stem cells: reprogramming a la carte. Nature Reviews Genetics, 12, 231.
28. Nair, V. (2008). Retrovirus-induced oncogenesis and safety of retroviral vectors. Current Opinion in Molecular Therapeutics, 10, 431.
29. Carey, B. W.; Markoulaki, S.; Hanna, J.; et al. (2009). Reprogramming of murine and human somatic cells using a single polycistronic vector. Proceedings of the National Academy of Sciences of the United States of America, 106, 157.
30. Somers, A.; Jean, J. C.; Sommer, C. A.; et al. (2010). Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells, 28, 1728.
31. Zhou, W.; Freed, C. R. (2009). Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells, 27, 2667.
32. Woltjen, K.; Michael, I. P.; Mohseni, P.; et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 458, 766.
33. Kaji, K.; Norrby, K.; Paca, A.; Mileikovsky, M.; Mohseni, P.; Woltjen, K. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 458, 771.
34. Okita, K.; Matsumura, Y.; Sato, Y.; et al. (2011). A more efficient method to generate integration-free human iPS cells. Nature Methods, 8, 409.
35. Yu, J.; Chau, K. F.; Vodyanik, M. A.; Jiang, J.; Jiang, Y. (2011). Efficient feeder-free episomal reprogramming with small molecules. PLoS One, 6, e17557.
36. Si-Tayeb, K.; Noto, F. K.; Sepac, A.; et al. (2010). Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Developmental Biology, 10, 81.
37. Zhou, H.; Wu, S.; Joo, J. Y.; et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 4, 381.
38. Kim, D.; Kim, C. H.; Moon, J. I.; et al. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 4, 472.
39. Fusaki, N.; Ban, H.; Nishiyama, A.; Saeki, K.; Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85, 348.
40. Warren, L.; Manos, P. D.; Ahfeldt, T.; et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7, 618.
41. Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917.
42. Luningschror P, Hauser S, Kaltschmidt B, Kaltschmidt C (2013) MicroRNAs in pluripotency, reprogramming and cell fate induction. Biochimica et Biophysica Acta
43. Subramanyam, D.; Lamouille, S.; Judson, R. L.; et al. (2011). Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nature Biotechnology, 29, 443.
44. Liao, B.; Bao, X.; Liu, L.; et al. (2011). MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. Journal of Biological Chemistry, 286, 17359.
45. Miyoshi, N.; Ishii, H.; Nagano, H.; et al. (2011). Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell, 8, 633.
46. Yang, C. S.; Li, Z.; Rana, T. M. (2011). microRNAs modulate iPS cell generation. RNA, 17, 1451.
47. Choi, Y. J.; Lin, C. P.; Ho, J. J.; et al. (2011). miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nature Cell Biology, 13, 1353.
48. Wang, J.; He, Q.; Han, C.; et al. (2012). p53-facilitated miR-199a-3p regulates somatic cell reprogramming. Stem Cells, 30, 1405.
49. Yang, C. S.; Rana, T. M. (2013). Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs. Molecular BioSystems, 9, 10.
50. Takahashi, K.; Tanabe, K.; Ohnuki, M.; et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861.
51. Lowry, W. E.; Richter, L.; Yachechko, R.; et al. (2008). Generation of human induced pluripotent stem cells from dermal fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 105, 2883.
52. Bao, L.; He, L.; Chen, J.; et al. (2011). Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors. Cell Research, 21, 600.
53. Maherali, N.; Ahfeldt, T.; Rigamonti, A.; Utikal, J.; Cowan, C.; Hochedlinger, K. (2008). A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell, 3, 340.
54. Stadtfeld, M.; Maherali, N.; Breault, D. T.; Hochedlinger, K. (2008). Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell, 2, 230.
55. Sauer, B.; Henderson, N. (1988). Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proceedings of the National Academy of Sciences of the United States of America, 85, 5166.
56. Chang, C. W.; Lai, Y. S.; Pawlik, K. M.; et al. (2009). Polycistronic lentiviral vector for hit and run reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells, 27, 1042.
57. Sauer, B. (1992). Identification of cryptic lox sites in the yeast genome by selection for Cre-mediated chromosome translocations that confer multiple drug resistance. Journal of Molecular Biology, 223, 911.
58. Cochrane, R. L.; Clark, S. H.; Harris, A.; Kream, B. E. (2007). Rearrangement of a conditional allele regardless of inheritance of a Cre recombinase transgene. Genesis, 45, 17.
59. Yusa, K.; Rad, R.; Takeda, J.; Bradley, A. (2009). Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nature Methods, 6, 363.
60. Fraser, M. J.; Ciszczon, T.; Elick, T.; Bauser, C. (1996). Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Molecular Biology, 5, 141.
61. Grabundzija, I.; Wang, J.; Sebe, A.; et al. (2013). Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucleic Acids Research, 41, 1829.
62. Kues, W. A.; Herrmann, D.; Barg-Kues, B.; et al. (2013). Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells. Stem Cells and Development, 22, 124.
63. Newman, J. C.; Bailey, A. D.; Fan, H. Y.; Pavelitz, T.; Weiner, A. M. (2008). An abundant evolutionarily conserved CSB-PiggyBac fusion protein expressed in Cockayne syndrome. PLoS Genetics, 4, e1000031.
64. Ivics, Z.; Hackett, P. B.; Plasterk, R. H.; Izsvak, Z. (1997). Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 91, 501.
65. Stadtfeld, M.; Nagaya, M.; Utikal, J.; Weir, G.; Hochedlinger, K. (2008). Induced pluripotent stem cells generated without viral integration. Science, 322, 945.
66. Okita, K.; Nakagawa, M.; Hyenjong, H.; Ichisaka, T.; Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322, 949.
67. Yu, J.; Hu, K.; Smuga-Otto, K.; et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324, 797.
68. Okita, K.; Yamakawa, T.; Matsumura, Y.; et al. (2013). An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells, 31, 458.
69. Su, R. J.; Baylink, D. J.; Neises, A.; et al. (2013). Efficient Generation of Integration-Free iPS Cells from Human Adult Peripheral Blood Using BCL-XL Together with Yamanaka Factors. PLoS One, 8, e64496.
70. Jia, F.; Wilson, K. D.; Sun, N.; et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nature Methods, 7, 197.
71. Narsinh, K. H.; Jia, F.; Robbins, R. C.; Kay, M. A.; Longaker, M. T.; Wu, J. C. (2011). Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nature Protocols, 6, 78.
72. Li, H. O.; Zhu, Y. F.; Asakawa, M.; et al. (2000). A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. Journal of Virology, 74, 6564.
73. Nagai, Y.; Kato, A. (2004). Accessory genes of the paramyxoviridae, a large family of nonsegmented negative-strand RNA viruses, as a focus of active investigation by reverse genetics. Current Topics in Microbiology and Immunology, 283, 197.
74. Shioda, T.; Iwasaki, K.; Shibuta, H. (1986). Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Research, 14, 1545.
75. Takimoto, T.; Taylor, G. L.; Connaris, H. C.; Crennell, S. J.; Portner, A. (2002). Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. Journal of Virology, 76, 13028.
76. Masaki, I.; Yonemitsu, Y.; Komori, K.; et al. (2001). Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 15, 1294.
77. Yonemitsu, Y.; Kitson, C.; Ferrari, S.; et al. (2000). Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nature Biotechnology, 18, 970.
78. Murakami, Y.; Ikeda, Y.; Yonemitsu, Y.; et al. (2008). Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes. The Journal of Gene Medicine, 10, 165.
79. Nishimura, K.; Sano, M.; Ohtaka, M.; et al. (2011). Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. Journal of Biological Chemistry, 286, 4760.
80. Hsu, M.; Scheid, A.; Choppin, P. W. (1981). Activation of the Sendai virus fusion protein (f) involves a conformational change with exposure of a new hydrophobic region. Journal of Biological Chemistry, 256, 3557.
81. Mizumoto, K.; Muroya, K.; Takagi, T.; Omata-Yamada, T.; Shibuta, H.; Iwasaki, K. (1995). Protein factors required for in vitro transcription of Sendai virus genome. Journal of Biochemistry, 117, 527.
82. Garcin, D.; Pelet, T.; Calain, P.; Roux, L.; Curran, J.; Kolakofsky, D. (1995). A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. The EMBO Journal, 14, 6087.
83. Hasan, M. K.; Kato, A.; Shioda, T.; Sakai, Y.; Yu, D.; Nagai, Y. (1997). Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3' proximal first locus. The Journal of General Virology, 78(Pt 11), 2813.
84. Inoue, M.; Tokusumi, Y.; Ban, H.; et al. (2003). Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. Journal of Virology, 77, 3238.
85. Nishishita, N.; Takenaka, C.; Fusaki, N.; Kawamata, S. (2011). Generation of human induced pluripotent stem cells from cord blood cells. Journal of Stem Cells, 6, 101.
86. Seki, T.; Yuasa, S.; Oda, M.; et al. (2010). Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell, 7, 11.
87. Seki, T.; Yuasa, S.; Fukuda, K. (2012). Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nature Protocols, 7, 718.
88. Ban, H.; Nishishita, N.; Fusaki, N.; et al. (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proceedings of the National Academy of Sciences of the United States of America, 108, 14234.
89. Nakanishi, M.; Otsu, M. (2012). Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Current Gene Therapy, 12, 410.
90. Griesenbach, U.; Inoue, M.; Meng, C.; et al. (2012). Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. American Journal of Respiratory and Critical Care Medicine, 186, 846.
91. Masaki, I.; Yonemitsu, Y.; Yamashita, A.; et al. (2002). Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circulation Research, 90, 966.
92. Kano, M.; Matano, T.; Nakamura, H.; et al. (2000). Elicitation of protective immunity against simian immunodeficiency virus infection by a recombinant Sendai virus expressing the Gag protein. AIDS, 14, 1281.
93. Griesenbach, U.; Inoue, M.; Hasegawa, M.; Alton, E. W. (2005). Sendai virus for gene therapy and vaccination. Current Opinion in Molecular Therapeutics, 7, 346.
94. Grudzien-Nogalska, E.; Kowalska, J.; Su, W.; et al. (2013). Synthetic mRNAs with superior translation and stability properties. Methods in Molecular Biology, 969, 55.
95. Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23, 165.
96. Hornung, V.; Ellegast, J.; Kim, S.; et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science, 314, 994.
97. Roitsch, T.; Lehle, L. (1989). Requirements for efficient in vitro transcription and translation: a study using yeast invertase as a probe. Biochimica et Biophysica Acta, 1009, 19.
98. Anderson, B. R.; Muramatsu, H.; Nallagatla, S. R.; et al. (2010). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Research, 38, 5884.
99. Darzynkiewicz, E.; Stepinski, J.; Ekiel, I.; et al. (1988). Beta-globin mRNAs capped with m7G, m2.7(2)G or m2.2.7(3)G differ in intrinsic translation efficiency. Nucleic Acids Research, 16, 8953.
100. Jemielity, J.; Fowler, T.; Zuberek, J.; et al. (2003). Novel anti-reverse cap analogs with superior translational properties. RNA, 9, 1108.
101. Pichlmair, A.; Schulz, O.; Tan, C. P.; et al. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science, 314, 997.
102. Kariko, K.; Weissman, D. (2007). Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Current Opinion in Drug Discovery & Development, 10, 523.
103. Kariko, K.; Muramatsu, H.; Welsh, F. A.; et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy: The Journal of the American Society of Gene Therapy, 16, 1833.
104. Motorin, Y.; Helm, M. (2011). RNA nucleotide methylation. Wiley Interdisciplinary Reviews RNA, 2, 611.
105. Mandal, P. K.; Rossi, D. J. (2013). Reprogramming human fibroblasts to pluripotency using modified mRNA. Nature Protocols, 8, 568.
106. Kormann, M. S.; Hasenpusch, G.; Aneja, M. K.; et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 29, 154.
107. Kariko, K.; Muramatsu, H.; Keller, J. M.; Weissman, D. (2012). Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Molecular Therapy: The Journal of The American Society of Gene Therapy, 20, 948.
108. Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013) Comparison of electrophysiological data from human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) to functional pre-clinical safety assays. Toxicological sciences: an official journal of the Society of Toxicology
109. Gai, H.; Leung, E. L.; Costantino, P. D.; et al. (2009). Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biology International, 33, 1184.
110. Zhang, J.; Wilson, G. F.; Soerens, A. G.; et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104, e30.
111. Ma, J.; Guo, L.; Fiene, S. J.; et al. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. American Journal of Physiology - Heart and Circulatory Physiology, 301, H2006.
112. Addis RC, Ifkovits JL, Pinto F, et al. (2013) Optimization of direct fibroblast reprogramming to cardiomyocytes using calcium activity as a functional measure of success. Journal of Molecular and Cellular Cardiology
113. Efe, J. A.; Hilcove, S.; Kim, J.; et al. (2011). Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nature Cell Biology, 13, 215.
114. Graf, T.; Enver, T. (2009). Forcing cells to change lineages. Nature, 462, 587.
115. Zhou, Q.; Brown, J.; Kanarek, A.; Rajagopal, J.; Melton, D. A. (2008). In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 455, 627.
116. Sekiya, S.; Suzuki, A. (2011). Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature, 475, 390.
117. Papp, B.; Plath, K. (2011). Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Research, 21, 486.
118. Zwi, L.; Caspi, O.; Arbel, G.; et al. (2009). Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation, 120, 1513.
119. Ieda, M.; Fu, J. D.; Delgado-Olguin, P.; et al. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 142, 375.
120. Papapetrou, E. P.; Tomishima, M. J.; Chambers, S. M.; et al. (2009). Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 106, 12759.
121. Hirai, H.; Tani, T.; Katoku-Kikyo, N.; et al. (2011). Radical acceleration of nuclear reprogramming by chromatin remodeling with the transactivation domain of MyoD. Stem Cells, 29, 1349.
122. Hirai, H.; Katoku-Kikyo, N.; Karian, P.; Firpo, M.; Kikyo, N. (2012). Efficient iPS cell production with the MyoD transactivation domain in serum-free culture. PLoS One, 7, e34149.